Trading Report: Today, Woodstock Corp decides to keep it stake in Bristol-Myers Squibb Co. (BMY) to the level of $1,518,000

Today, Woodstock Corp decides to keep it stake in Bristol-Myers Squibb Co. (BMY) to the level of $1,518,000

Woodstock Corp continued to hold its position in shares of Bristol-Myers Squibb Co. (NYSE:BMY) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,155 shares of the biopharmaceutical company’s stock at the end of the third quarter. Woodstock Corp’s holdings in Bristol-Myers Squibb were worth $1,518,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wills Financial Group Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.3% in the second quarter. Wills Financial Group Inc. now owns 3,509 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 10 shares during the period. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 2,353 shares of the biopharmaceutical company’s stock worth $173,000 after buying an additional 12 shares during the period. TRUE Private Wealth Advisors boosted its stake in shares of Bristol-Myers Squibb by 0.3% in the second quarter. TRUE Private Wealth Advisors now owns 5,377 shares of the biopharmaceutical company’s stock worth $395,000 after buying an additional 15 shares during the period. Bruderman Asset Management LLC boosted its stake in shares of Bristol-Myers Squibb by 0.4% in the second quarter. Bruderman Asset Management LLC now owns 4,258 shares of the biopharmaceutical company’s stock worth $313,000 after buying an additional 15 shares during the period. Finally, Stillwater Investment Management LLC boosted its stake in shares of Bristol-Myers Squibb by 0.5% in the second quarter. Stillwater Investment Management LLC now owns 3,467 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 16 shares during the period. Hedge funds and other institutional investors own 71.28% of the company’s stock.

Bristol-Myers Squibb Co. (NYSE:BMY) traded up 0.41% during midday trading on Friday, hitting $56.98. The company had a trading volume of 6,228,571 shares. Bristol-Myers Squibb Co. has a 52 week low of $49.03 and a 52 week high of $77.12. The stock has a 50 day moving average price of $52.69 and a 200 day moving average price of $63.10. The company has a market capitalization of $95.23 billion, a P/E ratio of 28.50 and a beta of 0.90.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.12. Bristol-Myers Squibb had a return on equity of 28.98% and a net margin of 18.54%. The business had revenue of $4.83 billion for the quarter, compared to the consensus estimate of $4.76 billion. During the same period in the prior year, the business posted $0.39 earnings per share. The company’s quarterly revenue was up 21.0% compared to the same quarter last year. Equities analysts forecast that Bristol-Myers Squibb Co. will post $2.85 earnings per share for the current fiscal year.

A number of analysts recently issued reports on the company. Jefferies Group reissued a “hold” rating and set a $58.00 price objective (up previously from $54.00) on shares of Bristol-Myers Squibb in a report on Monday, October 31st. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $58.77 price objective on the stock. in a report on Monday, November 7th. BMO Capital Markets reissued a “market perform” rating and set a $60.00 price objective on shares of Bristol-Myers Squibb in a report on Saturday, September 3rd. SunTrust Banks Inc. cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $86.00 to $68.00 in a report on Friday, August 5th. Finally, Berenberg Bank cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and lowered their price target for the company from $80.00 to $70.00 in a report on Thursday, August 11th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $67.51.

In other Bristol-Myers Squibb news, Director Lamberto Andreotti sold 21,600 shares of the company’s stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $56.87, for a total transaction of $1,228,392.00. Following the sale, the director now directly owns 334,499 shares in the company, valued at $19,022,958.13. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.24% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Related posts

Leave a Comment